| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2338 | 2019 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 552 | 2019 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 507 | 2019 |
| Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial S Del Prato, SE Kahn, I Pavo, GJ Weerakkody, Z Yang, J Doupis, ... The Lancet 398 (10313), 1811-1824, 2021 | 381 | 2021 |
| Targets for glycemic control SA Imran, G Agarwal, HS Bajaj, S Ross, ... Canadian journal of diabetes 42, S42-S46, 2018 | 266* | 2018 |
| Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial B Zinman, VR Aroda, JB Buse, B Cariou, SB Harris, ST Hoff, KB Pedersen, ... Diabetes care 42 (12), 2262-2271, 2019 | 221 | 2019 |
| Once-weekly insulin for type 2 diabetes without previous insulin treatment J Rosenstock, HS Bajaj, A Janež, R Silver, K Begtrup, MV Hansen, T Jia, ... New England Journal of Medicine 383 (22), 2107-2116, 2020 | 186 | 2020 |
| Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort SR Kashyap, DL Diab, AR Baker, L Yerian, H Bajaj, C Gray‐McGuire, ... Obesity 17 (9), 1696-1701, 2009 | 149 | 2009 |
| Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial MJ Jardine, Z Zhou, KW Mahaffey, M Oshima, R Agarwal, G Bakris, ... Journal of the American Society of Nephrology 31 (5), 1128-1139, 2020 | 148 | 2020 |
| Efficacy and safety of once-weekly semaglutide 2· 0 mg versus 1· 0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial JP Frías, P Auerbach, HS Bajaj, Y Fukushima, I Lingvay, S Macura, ... The Lancet Diabetes & Endocrinology 9 (9), 563-574, 2021 | 113 | 2021 |
| Diabetes and Ramadan: practical guidelines 2021 M Hassanein, B Afandi, MY Ahmedani, RM Alamoudi, F Alawadi, ... Diabetes research and clinical practice 185, 109185, 2022 | 95 | 2022 |
| Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial A Philis-Tsimikas, DC Klonoff, K Khunti, HS Bajaj, LA Leiter, MV Hansen, ... Diabetologia 63, 698-710, 2020 | 89 | 2020 |
| Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial EA Bohula, BM Scirica, SE Inzucchi, DK McGuire, AC Keech, SR Smith, ... The Lancet 392 (10161), 2269-2279, 2018 | 86 | 2018 |
| Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized … HS Bajaj, RM Bergenstal, A Christoffersen, MJ Davies, A Gowda, ... Diabetes Care 44 (7), 1586-1594, 2021 | 84 | 2021 |
| Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM) J Rosenstock, A Jelaska, F Wang, G Kim, U Broedl, HJ Woerle, HS Bajaj Canadian Journal of Diabetes 37, S32, 2013 | 75 | 2013 |
| Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial F Persson, P Rossing, P Vart, GM Chertow, FF Hou, N Jongs, ... Diabetes Care 44 (8), 1894-1897, 2021 | 71 | 2021 |
| A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt … HJL Heerspink, D Cherney, D Postmus, BV Stefánsson, GM Chertow, ... Kidney International 101 (1), 174-184, 2022 | 68 | 2022 |
| Lowest glucose variability and hypoglycemia are observed with the combination of a GLP-1 receptor agonist and basal insulin (VARIATION Study) HS Bajaj, K Venn, C Ye, A Patrick, S Kalra, H Khandwala, N Aslam, ... Diabetes Care 40 (2), 194-200, 2017 | 64 | 2017 |
| Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study MG Swain, A Ramji, K Patel, G Sebastiani, AA Shaheen, E Tam, P Marotta, ... Canadian Medical Association Open Access Journal 8 (2), E429-E436, 2020 | 56 | 2020 |
| Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a … C Mathieu, B Ásbjörnsdóttir, HS Bajaj, W Lane, ALSA Matos, S Murthy, ... The Lancet 401 (10392), 1929-1940, 2023 | 53 | 2023 |
